放疗后局部复发前列腺癌全腺体挽救性冷冻治疗的长期结局:两中心联合分析
本研究前瞻性纳入两中心1992至2004年因活检证实局部放疗难治性前列腺癌接受挽救性冷冻治疗的268例患者,中位随访10.3年。10年无ADT生存69%、无CRPC生存76%、疾病特异性生存81%、总生存77%;挽救前PSA>10 ng/ml与CRPC和ADT启动风险增加相关,新辅助ADT与更好OS和DSS相关。
要点
- 挽救性冷冻治疗10年无ADT生存69%、无CRPC生存76%。
- 10年疾病特异性生存81%,总生存77%,并发症可接受。
- 挽救前PSA>10 ng/ml与CRPC和ADT启动风险增加相关。
核心结论
- 对放疗难治性前列腺癌,挽救性冷冻治疗提供良好的长期无ADT、无CRPC和疾病特异性生存,且并发症可接受。
研究设计与样本
- 两中心前瞻性队列,纳入1992至2004年活检证实局部放疗难治性前列腺癌接受挽救性冷冻治疗的患者268例,中位随访10.3年。
主要发现
- 共记录223例并发症事件,其中Clavien I-II级168例,Clavien III级55例。
- 10年无ADT生存率为69%,10年无CRPC生存率为76%。
- 10年疾病特异性生存率为81%,10年总生存率为77%。
- 挽救前PSA>10 ng/ml与CRPC发生和ADT启动风险增加相关,但与DSS或OS无关。
- 使用新辅助ADT与OS和DSS改善相关,但不影响无CRPC生存或辅助ADT。
关键数值与推荐
- 10年无ADT生存率69%,无CRPC生存率76%,DSS率81%,OS率77%。
- 挽救前PSA>10 ng/ml与CRPC和ADT启动风险增加相关。
- 新辅助ADT与OS和DSS改善相关。
临床怎么用
- 对于放疗后局部复发前列腺癌,挽救性冷冻治疗可作为可行的局部治疗选择,需关注并发症。
- 挽救前PSA>10 ng/ml提示CRPC和ADT启动风险增加,应加强监测。
- 新辅助ADT可能改善OS和DSS,但需前瞻性试验验证。
局限性
- 需前瞻性试验验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation refractory prostate cancer (RRPCa) is common and salvage cryotherapy for RRPCa is emerging as a viable local treatment option. However, there is a paucity of long-term data. The purpose of this study is to determine long-term outcomes following salvage cryotherapy for RRPca. MATERIALS AND METHODS: Patients undergoing salvage cryotherapy for biopsy-proven, localized RRPCa from 1992 through 2004 were prospectively accrued at two centers. Preoperative characteristics, perioperative morbidity and postoperative data were reviewed from our database. The primary outcomes were overall survival (OS) and disease-specific survival (DSS). The secondary outcomes were freedom from castration-resistant prostate cancer (CRPC) and freedom from androgen deprivation therapy (ADT). RESULTS: A total of 268 patients were identified with a median followup of 10.3 years. A total of 223 complication events were recorded; of them, 168 were Clavien I-II events and 55 Clavien III events. At 10 years, 69% had freedom from ADT and 76% had freedom from CRPC. The 10-year DSS rate was 81%, and the 10-year OS rate was 77%. A pre-salvage prostate specific antigen level of >10 ng/ml was associated with an increased risk of developing CRPC and initiation of ADT but was not associated with DSS or OS. The use of neoadjuvant ADT was associated with improved OS and DSS but did not affect freedom from CRPC or adjuvant ADT. CONCLUSIONS: Salvage cryotherapy for RRPCa provides excellent long-term freedom from ADT, CRPC and DSS with acceptable morbidity. OS at 10 years was 77%. Prospective trials are required for validation.
引用
- Chin JL, Lavi A, Metcalfe MJ, et al. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. J Urol. 2021. PMID: 33908799. doi:10.1097/JU.0000000000001831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。